NCT01999348 - A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting | Biotech Hunter

Enrollment

1,553

Participants

Timeline

Start Date

November 25, 2013

Primary Completion Date

December 19, 2014

Study Completion Date

December 19, 2014

Conditions

Glaucoma, Primary Open AngleOcular Hypertension

Interventions

DRUG

Fixed Combination Bimatoprost and Timolol

Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.

Trial Locations (1)

Unknown

Wiesloch